Dunn, Julia P.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine

Obstructive Sleep Apnea ResearchPharmacology and Obesity Treatment

Cited by 871

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 638

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 634

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., et al. (2023) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 208

Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight

Look, M., Dunn, J. P., Kushner, R. F., Cao, D., Harris, C., Gibble, T. H., Stefanski, A., & Griffin, R. (2025) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 181

Decreased Dopamine Type 2 Receptor Availability After Bariatric Surgery: Preliminary Findings

Dunn, J. P., Cowan, R. L., Volkow, N. D., Feurer, I. D., Li, R., Williams, D. B., Kessler, R. M., & Abumrad, N. N. (2010) · Brain Research

Bariatric Surgery and OutcomesRegulation of Appetite and Obesity

Cited by 151

Relationship of Dopamine Type 2 Receptor Binding Potential With Fasting Neuroendocrine Hormones and Insulin Sensitivity in Human Obesity

Dunn, J. P., Kessler, R. M., Feurer, I. D., Volkow, N. D., Patterson, B. W., Ansari, M. S., Li, R., Marks-Shulman, P., & Abumrad, N. N. (2012) · Diabetes Care

Regulation of Appetite and ObesityNeurotransmitter Receptor Influence on Behavior

Cited by 148

Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies ( SURPASS programme)

Kiyosue, A., Dunn, J. P., Cui, X., Hickey, A., Hirase, T., Imaoka, T., & Heine, R. J. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 30

Regulation of novelty seeking by midbrain dopamine D2/D3 signaling and ghrelin is altered in obesity: Novelty Seeking in Obesity

Savage, S. W., Zald, D. H., Cowan, R. L., Volkow, N. D., Marks-Shulman, P. A., Kessler, R. M., Abumrad, N. N., & Dunn, J. P. (2014) · Obesity

Neurotransmitter Receptor Influence on BehaviorRegulation of Appetite and Obesity

Cited by 27

Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial

Mamas, M. A., Bays, H., Li, R., Upadhyay, N., Irani, T., Senyucel, C., Dunn, J. P., & Liu-Seifert, H. (2025) · European Heart Journal Open

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 24

Examining the evidence for weight management in individuals with type 2 diabetes

Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 18

Weight management treatment modalities in patients with overweight or obesity: A retrospective cohort study of administrative claims data

Kan, H., Swindle, J. P., Bae, J., Dunn, J. P., Buysman, E. K., Gronroos, N. N., Bengtson, L., Chinthammit, C., Ford, J., & Ahmad, N. (2023) · Obesity Pillars

Bariatric Surgery and OutcomesPharmacology and Obesity Treatment

Cited by 10

0572 Weight reduction and the impact on apnea-hypopnea index: a meta-analysis

Malhotra, A., Curtis, A., Dunn, J., Bunck, M. C., & Bednarik, J. (2023) · SLEEP

Obstructive Sleep Apnea ResearchSleep and related disorders

Cited by 2